Skip to main content
. 2022 Aug 29;119(36):e2202577119. doi: 10.1073/pnas.2202577119

Fig. 2.

Fig. 2.

IL-38 suppresses the inflammatory and osteogenic responses to proinflammatory stimulation in human AVICs from non-CAVD valves. (A) Human AVICs from non-CAVD valves were pretreated with recombinant IL-38 (10 ng/mL) for 2 h followed by matrilin-2 (2 µg/mL) treatment for 72 h. Representative immunoblots (Upper) and densitometric data (Lower) show that treatment with recombinant IL-38 reduced the inflammatory and osteogenic responses to matrilin-2. (B) ELISA data show that recombinant IL-38 suppressed the production of IL-6 and CCL2 in human AVICs from non-CAVD valves exposed to matrilin-2. (C) Representative images of Alizarin Red S staining and spectrophotometric data show that treatment for 14 d with recombinant IL-38 reduced calcium deposition in human AVICs from non-CAVD valves exposed matrilin-2. Values are mean ± SEM, n = 4 donors. **P < 0.01 and ***P < 0.001 versus vehicle; #P < 0.05 and ###P < 0.001 versus matrilin-2 alone. (Scale bar, 100 µm).